New Risk • Jun 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m (AU$1.1m revenue, or US$793k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$77.3m market cap, or US$54.2m). 공시 • Sep 23
LTR Pharma Limited, Annual General Meeting, Oct 24, 2025 LTR Pharma Limited, Annual General Meeting, Oct 24, 2025. Location: at the offices of k&l gates, 16/66 eagle street, qld 4000., brisbane Australia Reported Earnings • Aug 31
Full year 2025 earnings released: AU$3.34 loss per share (vs AU$0.05 loss in FY 2024) Full year 2025 results: AU$3.34 loss per share. Net loss: AU$5.59m (loss narrowed 20% from FY 2024). 공시 • Aug 18
LTR Pharma Limited Appoints Andrew Y. Sun to Its Scientific Advisory Board LTR Pharma Limited announced the appointment of Dr Andrew Y. Sun, M.D., a fellowship-trained urologist and nationally recognized expert in male sexual and reproductive medicine, to its Scientific Advisory Board. Based in Texas, Dr Sun brings extensive experience in prescribing PDE5 treatment protocols and will advise on integrating LTR's intranasal therapies ROXUS® and SPONTAN® into treatment pathways for erectile dysfunction, particularly for patients experiencing side effects with existing oral medications. Dr Sun is Director of Men's Health at Urology Partners of North Texas, one of the state's largest men's health clinics. He trained at Harvard Medical School, completed a residency at the Cleveland Clinic Glickman Urological and Kidney Institute, and undertook fellowship training in Male Reproductive Medicine and Surgery at UCLA. His clinical experience spans erectile dysfunction, ejaculatory dysfunction, male infertility, hormone management, and Peyronie's disease. Dr Sun is an active contributor to US national clinical guidelines and a frequent speaker at leading urology conferences. He is an active member of the American Urological Association, the American Society for Reproductive Medicine, and the International Society for Sexual Medicine. Dr Sun contributes to clinical guidelines for the Sexual Medicine Society of North America and leads national training programs in erectile restoration with Boston Scientific. As a thought leader in men's sexual health, Dr Sun is a frequent presenter at international scientific meetings and has authored multiple peer-reviewed journal articles. His expertise is widely recognized through regular appearances on prominent podcasts, including BackTable Urology, Bionic Health, and Urology Times' "Pearls & Perspectives", where he shares insights on testosterone therapy, men's health program development, and sexual dysfunction management. He has been interviewed at major conferences, including the American Urological Association annual meeting, reflecting his influential position within the urology community. 공시 • Apr 01
LTR Pharma Limited Announces Change of Company Secretary, Effective 1 April 2025 LTR Pharma Limited advised that in accordance with ASX Listing Rule 3.16.1, that Mr. David Hwang and Ms. Elizabeth Spooner of Confidant Partners have been appointed as Joint Company Secretaries, effective immediately.
For the purposes of ASX Listing Rule 12.6, Mr. David Hwang and Ms. Elizabeth Spooner will be the persons responsible for communications with ASX in relation to Listing Rule matters. Ms. Shelby Coleman will step down
as Company Secretary, effective immediately. Board Change • Feb 04
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Maja McGuire was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Dec 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Maja McGuire was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 공시 • Dec 11
LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 25 million. LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 25 million.
Security Name: Ordianry Shares
Security Type: Common Stock
Securities Offered: 27,173,913
Price\Range: AUD 0.92
Discount Per Security: AUD 0.0552
Transaction Features: Subsequent Direct Listing Board Change • Oct 03
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Maja McGuire was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 공시 • Jul 26
LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million. LTR Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 14,383,562
Price\Range: AUD 0.73
Discount Per Security: AUD 0.0438
Transaction Features: Subsequent Direct Listing New Risk • May 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$69.7m market cap, or US$46.5m).